1) ザガーロ添付文書, インタビューフォーム, 審査報告書
2) ザガーロ申請資料概要 a)薬理, b)非臨床概括, c)臨床概要
3) アボルブ添付文書, インタビューフォーム, 審査報告書
4) アボルブ申請資料概要 a)薬理, b)薬物動態, c)毒性, d)臨床概要
5) プロペンシア添付文書, インタビューフォーム, 審査報告書
6) プロペンシア申請資料概要 a)薬理, b)非臨床概括, c)臨床概要
7) Wilson JD et al ed Williams Textbook of Endocrinology 9th ed. WB Saunders Company, Philadelphia, 1998
8) 浜六郎, 木元康介, 5-α還元酵素阻害剤 (デュタステリド : アボルブ) : 高悪性度の前立腺癌を増加, TIP「正しい治療と薬の情報」2012 : 27 (6) : 86-91.
9) GSK press release ; http://www.gsk.com/en-gb/media/press-releases/2011/gsk-statement-on-avodart-dutasteride-for-prostate-cancer-risk-reduction/
10) a) 5α還元酵素阻害剤 (5-ARIs) : 添付文書の変更-前立腺癌のリスク増加 http://www.cancerit.jp/3651.html b) FDA ; 5-alpha reductase inhibitors (5-ARIs) : Label Change - Increased Risk of Prostate Cancer http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm258529.htm c) FDA Drug Safety Communication : 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer http://www.fda.gov/Drugs/DrugSafety/ucm258314.htm
11) 「デュタステリド 前立腺癌」でGoogle検索結果9470件 (2012年6月18日現在) a) http://glaxosmithkline.co.jp/press/press/2009_01/P1000553.html b) http://www.watarase.ne.jp/aponet/blog/110612.html c) http://medical-confidential.com/confidential/2012/07/post-427.html
12) WHO, Classification of Tumours Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs :
15) FDA Briefing Document ; Dec 1 2010) ; Part 2 : for AVODARTR (dutasteride) http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM234934.pdf.
16) Andriole GL et al (REDUCE Study Group) Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010 ; 362 (13) : 1192-202.
17) FDA Briefing Document ; Dec 1 2010) ; Part 1 For Proscar (finasteride).
19) Sykora I, Vortel V. Comparability of results of postnatal and long-term tests for carcinogenicity. Neoplasma. 1993 ; 40 : 321-7.
20) Li JJ et al, Relative carcinogenic activity of various synthetic and natural estrogens in the Syrian hamster kidney. Cancer Research 1983 ; 5200-4.
21) Li JJ et al. Carcinogenic activities of various steroidal and nonsteroidal estrogens in the hamster kidney : relation to hormonal activity and cell proliferation. Cancer Research 1995 ; 55 : 4347-51.
24) McConnell JD et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 ; 349 : 2387-98
27) GlaxoSmithKline, Briefing Document for ODAC01-December-2010 : Avodart for the Reduction of Risk of Prostate Cancer : http://www.fda.gov/downloads/Advisor.../UCM234936.pdf
28) http://rxisk.org/drugs-a-z/
29) 医薬品食品衛生研究所, 医薬品安全性情報 Vol.14 No.03 (2016/02/10)